Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Recruiting1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

recruiting133%
unknown133%
completed133%

Recent Activity

1 active trials
Showing 3 of 3
recruiting

Immune Homeostasis in Sepsis and Septic Shock

NCT04448951
unknown

Role of Cord Blood Cytokines and Perinatal Factors in Prediction of Retinopathy of Prematurity

NCT04769661
completedphase_1

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

NCT01576692

Clinical Trials (3)

Showing 3 of 3 trials
NCT04448951

Immune Homeostasis in Sepsis and Septic Shock

Recruiting
NCT04769661

Role of Cord Blood Cytokines and Perinatal Factors in Prediction of Retinopathy of Prematurity

Unknown
NCT01576692Phase 1

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Completed

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3